Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for patients with Short Bowel Syndrome


Osaka, Japan June 25 and Bedminster, NJ, June 22 2012 --- Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP, “NPS”), jointly announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (tradename in Europe: Revestive®) as a once-daily treatment for adult patients with short bowel syndrome (SBS). The marketing authorisation application was submitted in March 2011.

Read more


Top of page

Takeda Pharma